AU2003202091A1 - Guanidine derivatives - Google Patents

Guanidine derivatives

Info

Publication number
AU2003202091A1
AU2003202091A1 AU2003202091A AU2003202091A AU2003202091A1 AU 2003202091 A1 AU2003202091 A1 AU 2003202091A1 AU 2003202091 A AU2003202091 A AU 2003202091A AU 2003202091 A AU2003202091 A AU 2003202091A AU 2003202091 A1 AU2003202091 A1 AU 2003202091A1
Authority
AU
Australia
Prior art keywords
guanidine derivatives
guanidine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003202091A
Other versions
AU2003202091A8 (en
Inventor
George Martin Buckley
Hazel Joan Dyke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of AU2003202091A1 publication Critical patent/AU2003202091A1/en
Publication of AU2003202091A8 publication Critical patent/AU2003202091A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003202091A 2002-04-10 2003-01-28 Guanidine derivatives Abandoned AU2003202091A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0208224.6 2002-04-10
GBGB0208224.6A GB0208224D0 (en) 2002-04-10 2002-04-10 Chemical compounds
PCT/GB2003/000339 WO2003045901A2 (en) 2002-04-10 2003-01-28 Guanidine derivatives

Publications (2)

Publication Number Publication Date
AU2003202091A1 true AU2003202091A1 (en) 2003-06-10
AU2003202091A8 AU2003202091A8 (en) 2003-06-10

Family

ID=9934563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003202091A Abandoned AU2003202091A1 (en) 2002-04-10 2003-01-28 Guanidine derivatives

Country Status (3)

Country Link
AU (1) AU2003202091A1 (en)
GB (1) GB0208224D0 (en)
WO (1) WO2003045901A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
KR101562549B1 (en) 2005-05-10 2015-10-23 인사이트 홀딩스 코포레이션 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
TWI382974B (en) 2005-12-20 2013-01-21 Incyte Corp N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20070203140A1 (en) * 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
PE20110308A1 (en) 2008-07-08 2011-06-10 Incyte Corp 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLAMINE 2,3-DIOXYGENASE
CA2780333C (en) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
CN103458886B (en) 2010-12-08 2016-06-08 莱斯拉公司 Pyriconyl guanidine F1F0-atpase inhibitor and therapeutical uses thereof
HUE035881T2 (en) 2010-12-08 2018-05-28 Lycera Corp Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9580391B2 (en) 2012-06-08 2017-02-28 Lycera Corporation Saturated acyl guanidine for inhibition of F1F0-ATPase
WO2013185045A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof
US9221814B2 (en) 2012-06-08 2015-12-29 Lycera Corporation Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof
EP3066085B1 (en) 2013-11-08 2020-05-13 Incyte Holdings Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
AU2014363904B2 (en) 2013-12-10 2018-10-04 Lycera Corporation Trifluoromethyl pyrazolyl guanidine F1Fo-ATPase inhibitors and therapeutic uses thereof
JP2016539983A (en) 2013-12-10 2016-12-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Alkylpyrazolylguanidine F1F0-ATPase inhibitor and therapeutic use thereof
AU2014363907B2 (en) 2013-12-10 2018-10-04 Lycera Corporation N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
CN109970675A (en) * 2018-05-28 2019-07-05 中国医学科学院医药生物技术研究所 One group of thiourea compound and its preparation method and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
AU3128197A (en) * 1996-05-30 1998-01-05 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
US6420403B1 (en) * 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
EP1218353B1 (en) * 1999-07-07 2007-10-17 AstraZeneca UK Limited Quinazoline derivatives

Also Published As

Publication number Publication date
GB0208224D0 (en) 2002-05-22
WO2003045901A3 (en) 2003-07-31
AU2003202091A8 (en) 2003-06-10
WO2003045901A2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
AU2003220935A1 (en) Benzamide derivatives
EP2617709B8 (en) Guanidine derivatives as antiviral agents
EP1682493B8 (en) Amidoacetonitrile derivatives
AU2003255492A1 (en) Heterocyclic derivatives
AU2003281040A1 (en) Biaryl derivatives
AU2003201850A1 (en) N-alkylsulfonyl-substituted amide derivatives
AU2003211362A1 (en) N-hydroxycarboxamide derivative
EP1606277B8 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
AU2003202091A1 (en) Guanidine derivatives
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003278369A1 (en) 3-cyano-quinoline derivatives
EP1706373B8 (en) Amidoacetonitrile derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2003231370A1 (en) Amide derivatives
AU2003263323A1 (en) Quinazolinone derivatives
AU2003223475A1 (en) Substituted pyrazine derivatives
AU2003231459A1 (en) Pyrimidine derivative
AU2003235889A1 (en) Amide derivatives
AU2003238180A1 (en) 2-naphtamide derivatives
AU2003273398A1 (en) Aroyl-piperidine derivatives
AU2002249639A1 (en) Pyranocoumarin derivatives
AU2002368112A1 (en) Pyrimidine derivatives
AU2003255803A1 (en) Quinazolinone derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase